alpha adrenoceptor Inhibitors
1 drugsAbout alpha adrenoceptor
Alpha adrenoceptors, or α-adrenergic receptors, are GPCRs activated by catecholamines like norepinephrine and epinephrine. They regulate blood pressure, smooth muscle contraction, and neurotransmitter release.
Alpha adrenoceptors are therapeutic targets due to their involvement in key physiological functions; however, there is currently no genetic evidence linking them to specific diseases.
There is one FDA-approved drug, UPNEEQ, targeting alpha adrenoceptors. It is a small molecule developed by RVL PHARMS.
Top alpha adrenoceptor Drugs
RVL PHARMS is the only company with an approved drug.
Low competition may present an opportunity for new market entrants.
alpha adrenoceptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets alpha adrenoceptor, using small molecule modality.
Exploring alternative modalities like antibodies could provide differentiation.
alpha adrenoceptor Clinical Trials 15 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on alpha adrenoceptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 | 100% |
| Phase 2 | 2 | 1 | 1 | 0 | 50% |
| Phase 3 | 3 | 2 | 0 | 1 | 100% |
| Phase 4 | 6 | 3 | 0 | 3 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
alpha adrenoceptor Drug Approval Timeline (2020 - 2020)
The first and only drug, UPNEEQ, was approved in 2020.
Recent approval suggests potential for further innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 15 (6 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on alpha adrenoceptor. A trial counts if an approved drug acting on alpha adrenoceptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.